The drug tirzepatide has shown promising results in reducing sleep disturbances in patients with obesity and obstructive sleep apnea, with 40% to 50% of patients no longer needing a CPAP device. The drug also helped lower C-reactive protein levels, systolic blood pressure, and led to significant weight loss. The two double-blind randomized controlled trials demonstrated a significant reduction in the number of sleep disruption events on the apnea-hypopnea index, as well as a decrease in systolic blood pressure. Results show tirzepatide could provide an alternative treatment for patients who cannot tolerate or adhere to existing therapies for OSA. The study was supported by Eli Lilly.
Source link
Tirzepatide Significantly Reduces Sleep Disruptions
